NASDAQ:BLUE - bluebird bio Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $11.08
  • Forecasted Upside: 90.44 %
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 10 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$5.82
▼ -0.52 (-8.20%)

This chart shows the closing price for BLUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New bluebird bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLUE

Analyst Price Target is $11.08
▲ +90.44% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for bluebird bio in the last 3 months. The average price target is $11.08, with a high forecast of $23.00 and a low forecast of $3.00. The average price target represents a 90.44% upside from the last price of $5.82.

This chart shows the closing price for BLUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 14 contributing investment analysts is to hold stock in bluebird bio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 1 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 1 sell ratings
5/15/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 1 sell ratings
8/13/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 1 sell ratings
11/11/2021
  • 1 strong buy ratings
  • 2 buy ratings
  • 13 hold ratings
  • 1 sell ratings
2/9/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 12 hold ratings
  • 1 sell ratings
5/10/2022
  • 1 strong buy ratings
  • 1 buy ratings
  • 11 hold ratings
  • 1 sell ratings
7/9/2022
  • 1 strong buy ratings
  • 2 buy ratings
  • 11 hold ratings
  • 1 sell ratings
8/8/2022

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 10 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022BarclaysUpgradeUnderweight ➝ Equal Weight$3.00 ➝ $5.00Low
8/2/2022Raymond JamesUpgradeMarket Perform ➝ Outperform$8.00Low
5/17/2022Morgan StanleyLower Price TargetUnderweight$3.00Medium
5/10/2022WedbushLower Price TargetNeutral$10.00 ➝ $8.00High
5/10/2022BarclaysLower Price Target$4.00 ➝ $3.00High
4/6/2022SVB LeerinkLower Price TargetMarket Perform$10.00 ➝ $8.00Medium
4/6/2022CowenDowngradeOutperform ➝ Market PerformMedium
3/8/2022Wells Fargo & CompanyLower Price TargetEqual Weight$12.00 ➝ $8.00High
3/7/2022Morgan StanleyLower Price TargetUnderweight$6.00 ➝ $5.00Medium
3/7/2022SVB LeerinkLower Price TargetMarket Perform$11.00 ➝ $10.00Low
3/7/2022BarclaysDowngradeEqual Weight ➝ Underweight$13.00 ➝ $4.00Low
1/6/2022Morgan StanleyLower Price TargetUnderweight$11.00 ➝ $10.00Medium
1/3/2022The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
12/23/2021SVB LeerinkReiterated RatingHoldLow
11/12/2021Berenberg BankReiterated RatingHold$11.00Medium
11/12/2021BMO Capital MarketsLower Price TargetMarket Perform$21.00 ➝ $13.00Low
11/8/2021WedbushLower Price TargetNeutral$22.00 ➝ $11.00High
11/8/2021Royal Bank of CanadaLower Price TargetNeutral ➝ Sector Perform$26.00 ➝ $14.00High
11/8/2021Wells Fargo & CompanyLower Price TargetEqual Weight$25.00 ➝ $16.00High
11/8/2021BarclaysLower Price TargetEqual Weight$20.00 ➝ $13.00High
11/8/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$23.00 ➝ $10.00High
11/8/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$11.00High
9/22/2021MizuhoLower Price TargetBuy$29.00 ➝ $23.00High
8/10/2021William BlairInitiated CoverageMarket PerformMedium
8/10/2021BMO Capital MarketsLower Price TargetMarket Perform$29.00 ➝ $21.00High
8/10/2021Bank of AmericaLower Price TargetNeutral$41.00 ➝ $22.00High
8/10/2021MizuhoLower Price TargetBuy$70.00 ➝ $29.00High
8/10/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$63.00 ➝ $23.00High
8/10/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$60.00 ➝ $25.00High
8/9/2021Stifel NicolausLower Price TargetHold$31.00 ➝ $18.00High
8/9/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$64.00 ➝ $20.00High
8/1/2021SVB LeerinkReiterated RatingBuyLow
7/16/2021Morgan StanleyLower Price TargetEqual Weight$36.00 ➝ $35.00High
7/1/2021Berenberg BankDowngradeBuy ➝ Hold$35.00Low
6/15/2021OppenheimerReiterated RatingHoldMedium
6/10/2021SVB LeerinkInitiated CoverageBuyMedium
4/21/2021BMO Capital MarketsLower Price TargetMarket Perform$35.00 ➝ $31.00Medium
4/19/2021Morgan StanleyLower Price TargetEqual Weight$45.00 ➝ $36.00Medium
3/29/2021Piper SandlerBoost Price Target$30.00 ➝ $35.00High
3/29/2021Jefferies Financial GroupReiterated RatingBuyHigh
3/29/2021SVB LeerinkBoost Price TargetOutperform$69.00 ➝ $72.00N/A
3/29/2021BMO Capital MarketsBoost Price TargetMarket Perform$31.00 ➝ $35.00High
3/28/2021OppenheimerReiterated RatingHoldHigh
3/14/2021SVB LeerinkReiterated RatingBuyMedium
3/10/2021Stifel NicolausBoost Price Target$26.00 ➝ $31.00Medium
3/10/2021MizuhoUpgradeNeutral ➝ Buy$34.00 ➝ $69.00High
3/2/2021Morgan StanleyLower Price TargetEqual Weight$50.00 ➝ $45.00Medium
2/24/2021BarclaysLower Price TargetEqual Weight$31.00 ➝ $27.00Medium
2/17/2021BMO Capital MarketsBoost Price TargetMarket Perform$36.00 ➝ $56.00Low
2/17/2021Stifel NicolausLower Price TargetHold$48.00 ➝ $35.00Low
2/17/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
2/17/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$76.00 ➝ $39.00Low
2/16/2021OppenheimerDowngradeOutperform ➝ Market PerformLow
2/16/2021Bank of AmericaDowngradeBuy ➝ NeutralLow
2/16/2021WedbushDowngradeOutperform ➝ NeutralLow
2/16/2021MizuhoDowngradeBuy ➝ NeutralLow
2/16/2021Piper SandlerLower Price TargetNeutral$55.00 ➝ $35.00Low
2/16/2021William BlairDowngradeOutperform ➝ Market PerformLow
12/9/2020Maxim GroupDowngradeBuy ➝ HoldHigh
12/7/2020MizuhoReiterated RatingBuyHigh
11/11/2020Berenberg BankInitiated CoverageBuy$64.00Low
11/11/2020Morgan StanleyLower Price TargetEqual Weight$68.00 ➝ $50.00Low
11/6/2020WedbushLower Price TargetOutperform$81.00 ➝ $73.00Medium
11/5/2020Stifel NicolausDowngradeBuy ➝ Hold$77.00 ➝ $51.00Medium
11/5/2020BarclaysDowngradeOverweight ➝ Equal WeightHigh
11/5/2020JPMorgan Chase & Co.Lower Price TargetOverweight$140.00 ➝ $76.00High
11/5/2020Wells Fargo & CompanyLower Price TargetOverweight$94.00 ➝ $81.00High
11/5/2020SVB LeerinkLower Price TargetOutperform$133.00 ➝ $99.00High
11/5/2020Bank of AmericaLower Price TargetBuy$100.00 ➝ $81.00High
11/5/2020Royal Bank of CanadaLower Price TargetOutperform$100.00 ➝ $93.00High
11/5/2020OppenheimerLower Price TargetOutperform$111.00 ➝ $90.00High
11/5/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$108.00 ➝ $56.00High
11/4/2020Piper SandlerLower Price TargetNeutral$70.00 ➝ $55.00High
11/2/2020William BlairUpgradeMarket Perform ➝ OutperformMedium
10/19/2020MizuhoInitiated CoverageBuy$123.00Medium
8/31/2020OppenheimerInitiated CoverageBuy$111.00High
8/30/2020William BlairReiterated RatingHoldHigh
8/19/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/10/2020Morgan StanleyLower Price TargetEqual Weight$73.00 ➝ $68.00Medium
8/6/2020BMO Capital MarketsLower Price TargetOutperform$112.00 ➝ $108.00High
8/6/2020WedbushLower Price TargetOutperform$89.00 ➝ $81.00Medium
7/29/2020OppenheimerInitiated CoverageBuy$111.00High
7/13/2020Bank of AmericaLower Price TargetBuy$104.00 ➝ $100.00High
6/12/2020SVB LeerinkBoost Price TargetOutperform$129.00 ➝ $133.00Medium
6/1/2020OppenheimerInitiated CoverageBuy$111.00Low
5/28/2020Morgan StanleyBoost Price TargetEqual Weight$69.00 ➝ $73.00Medium
5/28/2020SVB LeerinkBoost Price TargetOutperform$125.00 ➝ $129.00Low
5/17/2020OppenheimerInitiated CoverageBuy$111.00Medium
5/13/2020BarclaysReiterated RatingBuyHigh
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$100.00High
5/12/2020BMO Capital MarketsBoost Price TargetOutperform$107.00 ➝ $112.00High
5/11/2020OppenheimerInitiated CoverageBuy$122.00 ➝ $111.00High
5/11/2020Piper SandlerLower Price TargetNeutral$75.00 ➝ $70.00High
4/15/2020Morgan StanleyLower Price TargetEqual Weight$92.00 ➝ $69.00Low
3/27/2020BMO Capital MarketsLower Price TargetOutperform$132.00 ➝ $107.00Low
3/27/2020William BlairReiterated RatingHoldMedium
3/26/2020Stifel NicolausUpgradeHold ➝ Buy$94.00 ➝ $70.00Low
3/26/2020Piper SandlerLower Price Target$85.00 ➝ $75.00Low
3/26/2020Wells Fargo & CompanyReiterated RatingBuyMedium
2/26/2020Morgan StanleyLower Price TargetEqual Weight$100.00 ➝ $92.00Low
2/20/2020OppenheimerLower Price Target$135.00 ➝ $128.00Low
2/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
2/19/2020Stifel NicolausLower Price TargetHold$96.00 ➝ $94.00High
2/3/2020Bank of AmericaInitiated CoverageBuy$120.00High
2/3/2020Evercore ISIUpgradeIn-Line ➝ Outperform$86.00 ➝ $100.00High
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
12/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$135.00High
12/10/2019William BlairReiterated RatingHoldHigh
12/9/2019Wells Fargo & CompanyLower Price TargetOverweight$242.00 ➝ $160.00High
12/6/2019CowenReiterated RatingBuyLow
11/27/2019Evercore ISIDowngradeOutperform ➝ In-LineMedium
11/26/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$119.00Low
11/21/2019CowenReiterated RatingBuyMedium
11/4/2019WedbushUpgradeNeutral ➝ Outperform$131.00 ➝ $124.00High
11/1/2019Stifel NicolausSet Price TargetHold$96.00Low
11/1/2019Morgan StanleySet Price TargetHold$104.00 ➝ $100.00Low
11/1/2019Maxim GroupReiterated RatingBuy$130.00Low
10/11/2019Morgan StanleyLower Price TargetEqual Weight$136.00 ➝ $104.00Medium
10/9/2019Stifel NicolausReiterated RatingHoldN/A
9/30/2019Stifel NicolausInitiated CoverageHold$109.00High
9/18/2019William BlairReiterated RatingHoldLow
8/12/2019William BlairDowngradeOutperform ➝ Market PerformHigh
8/6/2019Morgan StanleyLower Price TargetEqual Weight$143.00 ➝ $136.00Medium
7/19/2019GabelliReiterated RatingBuyN/A
6/18/2019Maxim GroupUpgradeHold ➝ Buy$160.00High
6/17/2019BMO Capital MarketsLower Price TargetOutperform$191.00 ➝ $163.00Low
6/14/2019Piper Jaffray CompaniesSet Price TargetHold$120.00Low
6/13/2019JPMorgan Chase & Co.Reiterated RatingBuy$195.00High
5/17/2019JPMorgan Chase & Co.Set Price TargetBuy$195.00Medium
5/16/2019SunTrust BanksLower Price TargetBuy$174.00Medium
5/15/2019WedbushDowngradeOutperform ➝ Neutral$166.00 ➝ $131.00Medium
5/3/2019BMO Capital MarketsSet Price TargetBuy$191.00High
5/3/2019William BlairReiterated RatingBuyMedium
4/23/2019William BlairReiterated RatingOutperformLow
3/22/2019Cantor FitzgeraldSet Price TargetHold$122.00Low
3/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
2/26/2019CowenInitiated CoverageOutperform$149.91High
2/25/2019SunTrust BanksLower Price TargetBuy$184.00High
2/22/2019BMO Capital MarketsBoost Price TargetOutperform$194.00Medium
2/22/2019Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$134.00 ➝ $122.00Medium
1/11/2019OppenheimerReiterated RatingHoldLow
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
12/19/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$165.00High
12/9/2018CowenReiterated RatingBuyLow
12/6/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$240.00 ➝ $120.00Medium
12/4/2018OppenheimerReiterated RatingHoldLow
12/4/2018William BlairReiterated RatingBuyLow
12/3/2018Janney Montgomery ScottSet Price TargetOutperform ➝ Buy$170.00High
12/3/2018Maxim GroupReiterated RatingHoldHigh
12/3/2018Cantor FitzgeraldReiterated RatingHold$134.00High
11/27/2018OppenheimerReiterated RatingHoldHigh
11/27/2018SVB LeerinkInitiated CoverageOutperform$145.00 ➝ $145.00Low
11/14/2018Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$155.00High
11/5/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$186.00 ➝ $185.00Low
11/5/2018WedbushLower Price TargetOutperform ➝ Outperform$204.00 ➝ $166.00Medium
11/5/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$170.00 ➝ $170.00Medium
11/4/2018Piper Jaffray CompaniesReiterated RatingBuyMedium
11/2/2018CowenReiterated RatingBuyMedium
11/2/2018OppenheimerReiterated RatingHoldLow
11/2/2018Cantor FitzgeraldUpgradeUnderweight ➝ Neutral$122.00 ➝ $134.00Medium
11/1/2018Maxim GroupReiterated RatingHoldMedium
11/1/2018William BlairReiterated RatingBuyHigh
10/15/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$190.00 ➝ $186.00Low
9/21/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
9/17/2018GuggenheimInitiated CoverageNeutralMedium
9/5/2018Cantor FitzgeraldSet Price TargetSell$122.00Low
9/5/2018William BlairReiterated RatingBuyMedium
8/23/2018Cantor FitzgeraldSet Price TargetSell$122.00Low
8/6/2018Maxim GroupReiterated RatingHoldLow
8/6/2018CowenReiterated RatingBuyLow
8/6/2018Cantor FitzgeraldSet Price TargetSell$122.00Medium
8/3/2018SunTrust BanksReiterated RatingBuy$223.00High
8/3/2018BMO Capital MarketsReiterated RatingBuy$208.00High
8/2/2018Piper Jaffray CompaniesReiterated RatingBuyMedium
7/30/2018Maxim GroupLower Price TargetHold$163.00Low
7/13/2018Cantor FitzgeraldSet Price TargetSell$122.00Medium
7/12/2018GabelliInitiated CoverageBuy$239.00Low
6/19/2018Evercore ISIUpgradeIn-Line ➝ Outperform$175.00 ➝ $230.00Low
6/5/2018Piper Jaffray CompaniesSet Price TargetBuy$240.00Low
6/4/2018Cantor FitzgeraldUpgradeUnderweight ➝ OverweightLow
6/4/2018CowenReiterated RatingBuyHigh
6/3/2018Cantor FitzgeraldSet Price TargetSell$122.00High
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Buy$240.00High
5/16/2018Cantor FitzgeraldReiterated RatingUnderweightLow
5/10/2018Cantor FitzgeraldReiterated RatingSell$122.00Medium
5/7/2018Sanford C. BernsteinReiterated RatingMarket Perform$211.00Low
5/3/2018Maxim GroupSet Price TargetHold$200.00High
5/3/2018BMO Capital MarketsLower Price TargetOutperform ➝ Buy$222.00 ➝ $216.00High
5/3/2018BTIG ResearchReiterated RatingBuyHigh
4/19/2018SunTrust BanksBoost Price TargetBuy$232.00High
3/21/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$152.00 ➝ $209.00High
3/16/2018William BlairReiterated RatingBuyMedium
3/16/2018UBS GroupInitiated CoverageSellHigh
3/14/2018Janney Montgomery ScottInitiated CoverageNeutral ➝ Neutral$220.00Medium
3/8/2018BTIG ResearchBoost Price TargetBuy$250.00Medium
3/5/2018William BlairInitiated CoverageOutperform ➝ Outperform$206.10 ➝ $242.00High
2/26/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$151.00 ➝ $152.00Medium
2/22/2018Maxim GroupReiterated RatingHold$200.00Medium
2/22/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$185.00 ➝ $218.00Medium
2/22/2018BMO Capital MarketsSet Price TargetOutperform ➝ Buy$215.00 ➝ $222.00High
2/22/2018Sanford C. BernsteinReiterated RatingHold$153.00 ➝ $211.00High
2/22/2018Cantor FitzgeraldLower Price TargetUnderweight$122.00 ➝ $113.00High
2/21/2018Cantor FitzgeraldReiterated RatingUnderweight ➝ Sell$122.00 ➝ $113.00High
1/25/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$162.00 ➝ $194.00Low
1/9/2018OppenheimerReiterated RatingHoldLow
12/21/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformHigh
12/20/2017OppenheimerInitiated CoverageMarket PerformLow
12/13/2017Maxim GroupDowngradeBuy ➝ Hold$200.00Medium
12/13/2017BarclaysReiterated RatingOverweight ➝ Overweight$162.00 ➝ $209.00High
12/12/2017SunTrust BanksBoost Price TargetBuy$223.00High
12/12/2017Wells Fargo & CompanyReiterated RatingOutperform$190.00 ➝ $242.00High
12/11/2017BMO Capital MarketsSet Price TargetBuy$215.00High
12/11/2017Jefferies Financial GroupUpgradeHold ➝ Buy$130.00 ➝ $211.00High
12/11/2017Cantor FitzgeraldSet Price TargetUnderweight ➝ Underweight$58.00 ➝ $113.00High
11/30/2017Maxim GroupBoost Price TargetBuy ➝ Buy$170.00 ➝ $200.00High
11/17/2017Maxim GroupSet Price TargetBuy$170.00N/A
11/3/2017SunTrust BanksBoost Price TargetBuy ➝ Buy$108.00 ➝ $163.00N/A
11/3/2017Jefferies Financial GroupReiterated RatingHold$130.00N/A
11/3/2017Morgan StanleyUpgradeUnderweight ➝ Equal WeightN/A
11/2/2017BarclaysBoost Price TargetOverweight$151.00 ➝ $162.00N/A
11/2/2017Maxim GroupReiterated RatingBuy$170.00N/A
11/2/2017WedbushReiterated RatingOutperform$135.00 ➝ $174.00N/A
11/2/2017BTIG ResearchUpgradeNeutral ➝ Buy$177.00N/A
11/1/2017SVB LeerinkReiterated RatingOutperform$145.00 ➝ $162.00N/A
11/1/2017Cantor FitzgeraldReiterated RatingSell$39.00 ➝ $58.00N/A
10/30/2017BMO Capital MarketsBoost Price TargetBuy$134.00 ➝ $162.00N/A
10/16/2017Evercore ISIUpgradeIn-Line ➝ Outperform$102.00N/A
10/11/2017Jefferies Financial GroupReiterated RatingBuy ➝ Hold$126.00N/A
10/9/2017Maxim GroupReiterated RatingBuy ➝ Buy$100.00 ➝ $170.00N/A
10/6/2017SVB LeerinkReiterated RatingOutperform$120.00 ➝ $145.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$186.00N/A
10/2/2017Morgan StanleyDowngradeEqual Weight ➝ Underweight$105.00High
9/30/2017SVB LeerinkReiterated RatingOutperform$120.00High
9/28/2017Cantor FitzgeraldReiterated RatingSell$39.00High
9/6/2017BarclaysInitiated CoverageOverweight$151.00Low
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$134.00 ➝ $158.00Medium
9/1/2017WedbushReiterated RatingOutperform$121.00 ➝ $135.00High
8/31/2017CowenReiterated RatingOutperformHigh
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$102.00High
8/11/2017Jefferies Financial GroupReiterated RatingBuy$88.00Medium
8/9/2017Morgan StanleyReiterated RatingHoldHigh
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/11/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/10/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
3/12/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/11/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/11/2022
  • 4 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/10/2022
  • 10 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
7/10/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/9/2022

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
bluebird bio logo
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.82
Low: $5.71
High: $6.11

50 Day Range

MA: $4.28
Low: $2.97
High: $6.34

52 Week Range

Now: $5.82
Low: $2.87
High: $25.39

Volume

83,808 shs

Average Volume

5,273,976 shs

Market Capitalization

$448.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

The following Wall Street sell-side analysts have issued stock ratings on bluebird bio in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Cowen Inc, Mizuho, Morgan Stanley, Raymond James, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BLUE.

What is the current price target for bluebird bio?

12 Wall Street analysts have set twelve-month price targets for bluebird bio in the last year. Their average twelve-month price target is $11.08, suggesting a possible upside of 90.4%. Mizuho has the highest price target set, predicting BLUE will reach $23.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for bluebird bio in the next year.
View the latest price targets for BLUE.

What is the current consensus analyst rating for bluebird bio?

bluebird bio currently has 1 sell rating, 10 hold ratings, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLUE, but not buy more shares or sell existing shares.
View the latest ratings for BLUE.

What other companies compete with bluebird bio?

How do I contact bluebird bio's investor relations team?

bluebird bio's physical mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (339) 499-9300 and its investor relations email address is [email protected] The official website for bluebird bio is www.bluebirdbio.com. Learn More about contacing bluebird bio investor relations.